How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | MOTS-c | NAD+ |
|---|---|---|
| ✓ | — | |
| — | ✓ |
What These Compounds Share
Key Differences
Compound Detail
MOTS-c
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
16-amino-acid mitochondrial-encoded peptide · 16 amino acids · Endogenous (mitochondrial-encoded)
Tap a target above for a plain-language explanation.
View Research Sources (1) →
Foundational mouse mechanistic work -- not converted into a human therapeutic claim on this record.
Supports: mechanism_summary, research_areas
NAD+
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Dinucleotide / coenzyme -- not a peptide · Endogenous
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (2) →
Measured plasma and urinary NAD+, nicotinamide, ADPR, methylnicotinamide and NMN at multiple timepoints. Real human PK-adjacent data on administered NAD+ itself, but a small pilot with no efficacy endpoint.
Supports: mechanism_summary, research_limitations
Reported moderate-to-severe infusion-related GI symptoms, increased heart rate and chest pressure during infusions (resolved by end of infusion), longer infusion times than nicotinamide riboside, and some lab-value changes (ALP decrease, HDL-C reduction). Real-world tolerability data, not a controlled efficacy trial. Authors are employees of the commercial IV-wellness company whose clients were reviewed -- a disclosed conflict of interest.
Supports: experimental_research
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist